← All trials
NCT05265507
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2022
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2022
- First posted
- Mar 3, 2022
- Last posted
- Mar 31, 2022
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chongqing Medical UniversityLead sponsor
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Government of ChinaCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Ninth People's Hospital of ChongqingCollaborator
- Chongqing Medical UniversityCollaborator
- The People's Hospital of NanchuanCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Chongqing Medical UniversityOverall official - principal investigator
- Chongqing Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Central South UniversityCollaborator
- Yunyang people's HospitalCollaborator
- Chongqing Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.